Solutions
Purpose-built for operators the standard market declines.
Most processors treat peptide and high-risk adjacent businesses as a liability to avoid. We built a program around the lawful lane — upfront compliance review, dedicated boarding, and a migration path that keeps your cash flow intact.
Who we serve
Four operator profiles. One consistent standard.
Each of these businesses has legitimate operations, real compliance infrastructure, and a processor problem that upfront underwriting can solve.
Research-Use-Only (RUO) B2B Sellers
You sell peptides wholesale to licensed researchers, labs, and clinics — B2B only, proper disclaimers, no consumer health claims. You have been frozen by aggregator processors whose risk models do not distinguish a lawful-lane B2B supplier from a consumer grey-market vendor. We do.
Rx-Licensed Operators
Your pharmacy or compounding operation holds the right licensure and follows prescribing protocols. What you lack is a processor that actually reads your compliance file before making a decision. We review your documentation upfront — not after you board.
Nutraceuticals & High-Risk Adjacents
Supplements, nootropics, and nutraceutical businesses that share a risk profile with the peptide category face the same aggregator freeze risk. If your category has been declined or de-platformed, we offer the same upfront underwriting review.
Multi-Entity Operators
Corporate structures with multiple DBAs, split-brand product lines, or an existing entity under freeze that needs a clean continuation path. We handle the documentation complexity and consolidate your review into a single pre-vet pass.
The problem
Compliant businesses face the same freeze risk as bad actors.
Aggregator-era processing was never designed for operators with legitimate compliance programs. The freeze is not a judgment on your business — it is a category flag. Our program is designed to look past the category.
Frozen accounts without warning
Aggregator processors terminate accounts when their automated risk scoring flags a category — not your specific business. A compliant operation pays the same price as a bad actor.
Declined without a file review
Most processors decline high-risk categories at intake without reading your compliance documentation, licenses, or business model. You get a form letter, not a decision.
Workarounds that amplify risk
MCC mismatch setups, processor-stacking, and offshore arrangements are fragile — and they flag the scrutiny they were meant to avoid. Compliant businesses deserve a durable first-party solution.
What makes us different
Upfront underwriting is the product.
The statement review is not a sales call. It is a real compliance read of your business — fees in plain language, a posture assessment, and a straight answer on whether we can board you. Operators who have been burned by teaser commitments that changed post-boarding value this more than a low headline number.
- Dedicated MID — not shared with other merchants in your category
- Upfront document review before you board, not after you go live
- Compliance read of your disclaimers, B2B gating, and licensing posture
- Pre-vet decision delivered within 24 hours of a complete file
- Plain-English findings — we tell you what we can and cannot accept and why
- Parallel-run migration path so you never operate without a live processor
- No obligation to proceed after the free review — the analysis is yours to keep
- Direct underwriting contact — no account manager relay when questions arise
Compliance first
We board the lawful lane. That selectivity is what keeps the program bankable.
We do not board consumer health-claim sellers, human-dosing product lines, or operations without proper B2B gating and disclaimer infrastructure. Our selectivity is not a marketing stance — it is the underwriting discipline that makes durable boarding possible for the operators we do serve.
Documentation review first
Licenses, disclaimers, B2B gating controls, and business model structure are reviewed before any boarding decision. No surprises post-launch.
Dedicated MID protection
Your account is not co-mingled with other merchants in your category. A problem elsewhere in the portfolio does not cascade to your processing.
Straight answers on fit
If we cannot board you, we tell you exactly why within 24 hours of a complete file — so you can address the gap or make an informed decision about alternatives.
Multi-entity operators
Complex structures reviewed as a single pre-vet pass.
If you operate multiple DBAs, maintain split product lines across entities, or need to establish a continuation path after an existing entity was frozen, we handle the documentation complexity in one consolidated review — not entity by entity.
DBA consolidation
Multiple brands under a single operator can be reviewed together, with a clear map of which entities and product lines are in-scope for boarding.
Continuation path planning
If an existing entity carries risk history, we help structure the continuation path — including migration strategy and documentation requirements — before the file goes to underwriting.
Principal-level review
Beneficial ownership and principal background are reviewed at pre-vet, not surfaced as a surprise during formal underwriting.
Single 24-hour turnaround
Complex structures get the same turnaround commitment: a plain-English pre-vet decision within 24 hours of a complete documentation set.
Start with a free statement review. No obligation.
Upload one recent processing statement. We return a plain-English compliance read and pre-vet assessment within 24 hours — yours to keep regardless of whether you proceed.